Google
Top Midday Decliners
MapLight Therapeutics' (MPLT) shares tumbled 68% even after the company said its phase 2 trial of ML
PREMIUM
Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.
Upgrade
Already have a subscription? Sign in
